Avalo Therapeutics, Inc. Common Stock (AVTX) Stock Price

AVTXStock

$11.27−19.50%52W

Market Cap$604.41M

P/E—

PEG Ratio—

Div yield—

Beta0.64

AVTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-28.83%

Price vs S&P 500 (4W)-28.98%

VGM Score21.76

Book Value / Share (Quarterly)$8.48

P/TBV (Annual)8.32x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-85.16%

Cash Flow / Share (Quarterly)$-1.29

Price vs S&P 500 (YTD)-49.87%

Gross Margin (TTM)242.18%

Net Profit Margin (TTM)-23254.24%

EPS (TTM)$-4.75

10-Day Avg Trading Volume0.93M

EPS Excl Extra (TTM)$-4.75

Revenue Growth (5Y)-61.19%

EPS (Annual)$-5.84

ROI (Annual)-91.66%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)-28808.30%

Cash / Share (Quarterly)$7.57

Revenue Growth QoQ (YoY)-69.27%

ROA (Last FY)-67.20%

Revenue Growth TTM (YoY)-86.62%

EBITD / Share (TTM)$-3.80

ROE (5Y Avg)-235.32%

Operating Margin (TTM)-33461.02%

Cash Flow / Share (Annual)$-2.78

P/B Ratio1.35x

P/B Ratio (Quarterly)2.17x

Net Income / Employee (Annual)$-2,371,500

EV / Revenue (TTM)8830.98x

Net Interest Coverage (TTM)-14.11x

ROA (TTM)-48.22%

EPS Incl Extra (Annual)$-5.84

Current Ratio (Annual)8.14x

Quick Ratio (Quarterly)18.95x

3-Month Avg Trading Volume1.20M

52-Week Price Return-19.50%

Revenue / Employee (TTM)$1,800

Tangible BV / Share (Quarterly)$162.64

P/S Ratio (Annual)10244.24x

Asset Turnover (Annual)0.00x

52-Week High$24.27

Operating Margin (5Y Avg)-28457.57%

EPS Excl Extra (Annual)$-5.84

26-Week Price Return-18.92%

Quick Ratio (Annual)7.60x

13-Week Price Return-41.82%

Total Debt / Equity (Annual)0.03x

Current Ratio (Quarterly)19.31x

Enterprise Value$521.03M

Revenue / Share Growth (5Y)-89.14%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$1,800

Inventory Turnover (Annual)128.40x

Pretax Margin (Annual)-132362.71%

Cash / Share (Annual)$5.31

3-Month Return Std Dev57.26%

Gross Margin (5Y Avg)93.92%

Net Income / Employee (TTM)$-3,040,400

ROE (Last FY)-94.23%

Net Interest Coverage (Annual)-3.00x

EPS Basic Excl Extra (Annual)$-5.84

Receivables Turnover (TTM)58.29x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-4.75

Receivables Turnover (Annual)34.06x

ROI (TTM)-57.29%

P/S Ratio (TTM)10244.24x

Pretax Margin (5Y Avg)-28747.65%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$590.87

Price vs S&P 500 (52W)-35.03%

Year-to-Date Return-37.94%

5-Day Price Return-14.88%

EPS Normalized (Annual)$-5.84

ROA (5Y Avg)-94.16%

Net Profit Margin (Annual)-132642.37%

Month-to-Date Return-26.48%

Cash Flow / Share (TTM)$-1.61

EBITD / Share (Annual)$-5.41

Operating Margin (Annual)-123601.69%

LT Debt / Equity (Annual)0.02x

ROI (5Y Avg)-168.09%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-4.75

P/TBV (Quarterly)12.89x

P/B Ratio (Annual)3.97x

Inventory Turnover (TTM)128.50x

Pretax Margin (TTM)-23033.90%

Book Value / Share (Annual)$4.49

Price vs S&P 500 (13W)-44.50%

Beta0.64x

P/FCF (Annual)48.14x

Revenue / Share (TTM)$0.00

ROE (TTM)-58.03%

52-Week Low$11.23

vGradeD

gGradeF

mGradeD

vgmGradeD

AVTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.62	-$0.83	-34.52%(-$0.21)
Q1 2026	May 13, 2026	-$1.07	-$0.98	+8.55%(+$0.09)
Q4 2025	Mar 23, 2026	-$1.50	-$0.37	+75.25%(+$1.13)
Q3 2025	Nov 6, 2025	-$1.64	-$2.19	-33.70%(-$0.55)
Q2 2025	Aug 7, 2025	-$1.46	-$1.92	-31.73%(-$0.46)

AVTX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.37

4.40

4.43

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
AVTXAvalo Therapeutics, Inc. Common Stock	D	F	D	10244.2x	-86.6%	242.2%	—	$11.27
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Avalo Therapeutics, Inc. Common Stock

Avalo Therapeutics is a clinical-stage biotechnology company developing monoclonal antibodies and fusion proteins to treat immune dysregulation disorders. The company's lead asset, AVTX-009, is an anti-IL-1B monoclonal antibody targeting inflammatory diseases. Additional pipeline candidates include quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

AVTX Next Earnings Report

Report dateNov 12, 2026

QuarterQ3 2026

Report timeBMO

EPS estimate-$0.56

Revenue estimate$0

Also reporting on Nov 12, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

AVTX Insider Transactions

SellSep 10, 2026
SULLIVAN CHRISTOPHER RYAN
Chief Financial Officer
Shares: 10,185Value: $179,457
SellAug 28, 2026
DOYLE MITTIE
Officer
Shares: 679Value: $13,580
SellAug 18, 2026
SULLIVAN CHRISTOPHER RYAN
Chief Financial Officer
Shares: 72,725Value: $1.45M
SellAug 17, 2026
DOYLE MITTIE
Officer
Shares: 1,000Value: $20,000
SellAug 11, 2026
RILEY JENNIFER
Officer
Shares: 2,655Value: $52,012

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

PRMEPrime Medicine, Inc. Common StockBiological Products
ATTOAttovia Therapeutics, Inc. Common StockBiological Products
CADLCandel Therapeutics, Inc. Common StockBiological Products
PCTPureCycle Technologies, Inc. Common stockPlastics & Resins
SLDBSolid Biosciences Inc. Common StockBiological Products
DBVTDBV Technologies S.A. American Depositary SharesBiological Products
TROXTRONOX LIMITED CL A ORDINARY SHARESIndustrial Chemicals
ETRAElectra Therapeutics, Inc. Common stockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.4

Strong Buy

Consensus rating

52-Week Range

Low$11.23

High$24.27